Biotechnology

Nektar Therapeutics

$18.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.72 (+4.06%) As of 4:05 PM UTC today

Why Robinhood?

You can buy or sell NKTR and other stocks, options, and ETFs commission-free!

About NKTR

Nektar Therapeutics Common Stock, also called Nektar Therapeutics, is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA. The listed name for NKTR is Nektar Therapeutics Common Stock.

CEO
Howard W. Robin
Employees
723
Headquarters
San Francisco, California
Founded
1990
Market Cap
3.38B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.23M
High Today
$18.75
Low Today
$17.83
Open Price
$17.85
Volume
439.49K
52 Week High
$25.06
52 Week Low
$13.63

Collections

NKTR Earnings

-$0.80
-$0.53
-$0.27
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

PDYPY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure